Photo from ASCO/X
Dec 29, 2023, 05:18
U.S. FDA summarizes their decision to restrict the approval of olaparib + abiraterone – American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology (ASCO) shared on their X/Twitter page:
”Breaking from Journal of Clinical Oncology: U.S. FDA summarizes their decision to restrict the approval of olaparib + abiraterone to patients with BRCA-mutated mCRPC rather than grant approval for all patients. Read in ASCO Daily News.”